Matched placebo for comparator teriflunomide
Sponsors
Sanofi-Aventis Research & Development, Sanofi-Aventis Recherche & Developpement
Conditions
Nervous system diseasesmultiple sclerosis
Phase 3
An interventional, Phase 3 extension study to investigate long-term safety and tolerability of tolebrutinib in participants with relapsing multiple sclerosis, primary progressive multiple sclerosis, or nonrelapsing secondary progressive multiple sclerosis
WithdrawnCTIS2023-503631-18-00
Target: 75Updated: 2023-11-27
Randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of multiple sclerosis
RecruitingCTIS2023-504358-36-00
Start: 2024-10-17Target: 386Updated: 2026-01-10
An interventional, Phase 3 extension study to investigate long-term safety and tolerability of tolebrutinib in participants with relapsing multiple sclerosis, primary progressive multiple sclerosis, or nonrelapsing secondary progressive multiple sclerosis
Active, not recruitingCTIS2023-503631-18-01
Start: 2024-05-20Target: 1405Updated: 2025-11-11
Randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of multiple sclerosis
RecruitingCTIS2024-514343-29-00
Start: 2024-11-19Target: 410Updated: 2026-01-10